Kang
|
2006
|
Korean
|
I-IV
|
platinum-based chemotherapy
|
Snapshot
|
60
|
15
|
5
|
0
|
20
|
16
|
4
|
0.763
|
8
|
Smith
|
2007
|
USA
|
I-IV
|
platium ± paditaxel chemotherapy
|
PCR–RFLP
|
176
|
11
|
22
|
15
|
23
|
60
|
45
|
0.701
|
8
|
Steffensen
|
2008
|
Danish
|
II-IV
|
carboplatin and cyclophosphamide combined-chemotherapy
|
TaqMan assay-based Real time PCR
|
100
|
3
|
7
|
2
|
12
|
34
|
42
|
0.239
|
8
|
Steffensen
|
2011
|
Danish
|
I-IV
|
Combined with carboplatin and paclitaxel
|
PCR–RFLP
|
157
|
2
|
4
|
7
|
15
|
71
|
58
|
0.321
|
8
|
Bösmüller
|
2011
|
Germany
|
I-III
|
Standard carboplatin-taxane
|
PCR–RFLP
|
41
|
6
|
5
|
3
|
7
|
9
|
11
|
0.098
|
8
|
Moxley
|
2013
|
USA
|
IIIB-IV
|
Platium- Based Chemotherapy
|
PCR–RFLP
|
64
|
10
|
13
|
9
|
14
|
8
|
10
|
0.005
|
8
|
Qi BL
|
2013
|
China
|
I-IV
|
Platinum-based combination
|
Snapshot
|
220
|
38
|
26
|
9
|
78
|
67
|
2
|
0.003
|
7
|
Huo XY
|
2017
|
China
|
I-IV
|
TP (paclitaxel / docetaxel + cisplatin / carboplatin / oxaliplatin)
|
PCR–RFLP
|
280
|
43
|
29
|
16
|
104
|
82
|
6
|
0.049
|
7
|
Yang SY
|
2017
|
China
|
III-IV
|
Cisplatin / carboplatin, combined with cyclophosphamide / paclitaxel
|
PCR–RFLP
|
209
|
28
|
31
|
12
|
70
|
67
|
1
|
0.000
|
7
|
Bao Y
|
2020
|
China
|
II-IV
|
cisplatin based Chemotherapy
|
PCR–RFLP
|
559
|
209
|
124
|
47
|
115
|
55
|
9
|
0.473
|
8
|